<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597478</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0137</org_study_id>
    <secondary_id>NCI-2015-02132</secondary_id>
    <nct_id>NCT02597478</nct_id>
  </id_info>
  <brief_title>Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea</brief_title>
  <official_title>A Preliminary Study of Prophylactic Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INSYS Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if fentanyl can help shortness of breath&#xD;
      in cancer patients. Researchers also want to learn if the study drug can help to improve your&#xD;
      physical function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If you agree to take part in this study, the study staff will collect information from your&#xD;
      medical record about your age, sex, race, and disease type, as well as how well you are able&#xD;
      to perform the normal activities of daily living, any drugs you are taking, and any possible&#xD;
      causes of shortness of breath.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      You will be randomly assigned (as in the flip of a coin) to receive either low-dose or&#xD;
      high-dose fentanyl spray. This is done because no one knows if one study group is better, the&#xD;
      same, or worse than the other group.&#xD;
&#xD;
      Study Visit:&#xD;
&#xD;
      During your study visit, you will complete 2 questionnaires about any breathing problems or&#xD;
      other symptoms you may be having. It should take about 10 minutes total to complete these&#xD;
      questionnaires.&#xD;
&#xD;
      You will blow into a device called a spirometer a few times to measure your lung function.&#xD;
      You will also be asked to inhale into another device called a negative inspiratory force&#xD;
      meter (NIF). This device measures the volume of air that can be inhaled after normal&#xD;
      breathing.&#xD;
&#xD;
      The study staff will then record your vital signs (heart rate, breathing rate, blood&#xD;
      pressure, and your blood-oxygen level). Your blood-oxygen level will be measured with a&#xD;
      device that will be clipped gently onto your fingertip). You will then be asked how hard it&#xD;
      is to catch your breath and to rate your level of tiredness.&#xD;
&#xD;
      When instructed, you will walk back and forth between 2 cones in an indoor hallway for up to&#xD;
      12 minutes. This is called the Shuttle Walk Test. The purpose of this timed test is to see&#xD;
      how far and fast you can walk without stopping for a rest. You will be asked to pivot briskly&#xD;
      around the cones and continue back the other way. You may stop this test at any time if you&#xD;
      feel you cannot continue.&#xD;
&#xD;
      After that, you will sit down and rest for up to 1 hour. During this time, the study drug&#xD;
      will be prepared, and you may be asked at different times how hard it is to catch your&#xD;
      breath.&#xD;
&#xD;
      After the rest period, you will be given the fentanyl to spray into your mouth and under your&#xD;
      tongue. About 10 minutes later, you will be asked about any side effects you may be having.&#xD;
&#xD;
      At that point, you will perform a second Shuttle Walk Test. Then the study staff will ask you&#xD;
      again about any side effects you may be having, your level of tiredness, and how hard it is&#xD;
      to catch your breath. Your vital signs will also be measured. The total distance you walked&#xD;
      will also be recorded.&#xD;
&#xD;
      After each walk test, you will also be asked to complete 4 tests of your mental abilities,&#xD;
      including finger tapping, simple math questions (addition, subtraction, multiplication,&#xD;
      division), recall of numbers, and recall of objects. It should take 15 minutes total to&#xD;
      complete these tests.&#xD;
&#xD;
      At the end of the study visit, you will be asked which dose level of the study drug you think&#xD;
      you received (high-dose or low-dose). You will also complete a questionnaire about how the&#xD;
      study drug may have helped you and how satisfied you are with the study. It should take about&#xD;
      5 minutes to complete the questionnaire.&#xD;
&#xD;
      At the end of the study, if you think that taking fentanyl helped to improve your breathing,&#xD;
      your doctor will be told, so that you and your doctor may discuss if fentanyl would be&#xD;
      helpful to you in the future.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      Your active participation in this study is over after you complete the last questionnaire.&#xD;
      You will be taken off study if intolerable side effects occur or if you are unable to follow&#xD;
      study directions.&#xD;
&#xD;
      Follow-Up:&#xD;
&#xD;
      Fourteen (14) days after your study visit you will be called by the study staff and asked how&#xD;
      you are feeling and about any side effects you may be having. This call should last about 10&#xD;
      minutes.&#xD;
&#xD;
      This is an investigational study. Fentanyl is FDA approved and commercially available for the&#xD;
      treatment of pain. Its use to control shortness of breath is investigational.&#xD;
&#xD;
      Up to 30 participants will be enrolled in this study. All will take part at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2016</start_date>
  <completion_date type="Actual">January 27, 2021</completion_date>
  <primary_completion_date type="Actual">September 27, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Dyspnea Borg Scale (Dyspnea Intensity)</measure>
    <time_frame>Before and after the first and second shuttle walk tests</time_frame>
    <description>The primary outcome was dyspnea intensity &quot;now&quot; using the modified Borg scale, which ranges from 0 (&quot;no shortness of breath&quot;) to 10 (&quot;worst possible shortness of breath&quot;). We measured the change in modified dyspnea Borg scale (0-10) between the first and second shuttle walk tests. This scale has been validated in multiple studies, with a minimal clinically significant difference of 1 point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Dyspnea Borg Scale (Dyspnea Unpleasantness)</measure>
    <time_frame>Before and after the first and second shuttle walk tests</time_frame>
    <description>The modified Borg scale (dyspnea unpleasantness), which ranges from 0 (&quot;no shortness of breath&quot;) to 10 (&quot;worst possible shortness of breath&quot;). We measured the change in modified dyspnea Borg scale (0-10) between the first and second shuttle walk tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walk Distance</measure>
    <time_frame>After the first shuttle walk test and after the second shuttle walk test</time_frame>
    <description>We measured the difference in walk distance (in meters) between the first and second shuttle walk tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walk Time</measure>
    <time_frame>After the first shuttle walk test and after the second shuttle walk test</time_frame>
    <description>We measured the difference in walk time (in minutes) between the first and second shuttle walk tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Modified Borg Score</measure>
    <time_frame>Before and after the first and second shuttle walk tests</time_frame>
    <description>The fatigue modified Borg scale, which ranges from 0 (&quot;none&quot;) to 10 (&quot;worst&quot;). We measured the change in modified fatigue Borg scale (0-10) between the first and second shuttle walk tests.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Advanced Cancers</condition>
  <arm_group>
    <arm_group_label>Low-Dose Fentanyl Spray Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving low-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. Low-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose Fentanyl Spray Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving high-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. High-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl Sublingual Spray</intervention_name>
    <description>Low-dose Fentanyl Goup: 15-25% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.&#xD;
High-Dose Fentanyl Group: 35-45% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.</description>
    <arm_group_label>High-Dose Fentanyl Spray Group</arm_group_label>
    <arm_group_label>Low-Dose Fentanyl Spray Group</arm_group_label>
    <other_name>Fentanyl SL Spray</other_name>
    <other_name>FSS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Shuttle Walk Test</intervention_name>
    <description>Participants walk back and forth between 2 cones in an indoor hallway for up to 12 minutes. After one hour Fentanyl Spray delivered, then second walk test performed.</description>
    <arm_group_label>High-Dose Fentanyl Spray Group</arm_group_label>
    <arm_group_label>Low-Dose Fentanyl Spray Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Questionnaire completed about any breathing problems or other symptoms participant may be having at baseline. End of study questionnaire asks which dose level of study drug participant thinks they received. Participant also completes a questionnaire about how study drug may have helped them and how satisfied they are with the study. It should take about 5 minutes to complete the questionnaire.</description>
    <arm_group_label>High-Dose Fentanyl Spray Group</arm_group_label>
    <arm_group_label>Low-Dose Fentanyl Spray Group</arm_group_label>
    <other_name>Surveys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mental Ability Tests</intervention_name>
    <description>After each walk test, participant completes 4 tests of their mental abilities. It should take 15 minutes total to complete these tests.</description>
    <arm_group_label>High-Dose Fentanyl Spray Group</arm_group_label>
    <arm_group_label>Low-Dose Fentanyl Spray Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Phone Call</intervention_name>
    <description>Thirty days study visit participant called by study staff. This call should last about 10 minutes.</description>
    <arm_group_label>High-Dose Fentanyl Spray Group</arm_group_label>
    <arm_group_label>Low-Dose Fentanyl Spray Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of cancer with evidence of active disease&#xD;
&#xD;
          2. Breakthrough dyspnea, defined as dyspnea with an average intensity level over the past&#xD;
             7 days of at least 3/10 on a numeric rating scale upon significant exertion or&#xD;
             continuous dyspnea &lt;/=7/10 with worsening upon significant exertion&#xD;
&#xD;
          3. Outpatient at MD Anderson Cancer Center seen by the Supportive Care Service, Thoracic&#xD;
             Medical Oncology, Cancer Pain Clinic, or Cardiopulmonary clinic&#xD;
&#xD;
          4. Ambulatory and able to walk with or without walking aid&#xD;
&#xD;
          5. On strong opioids with morphine equivalent daily dose of 80-500 mg for at least one&#xD;
             week, with stable (i.e. +/- 30%) regular dose over the last 24 hours&#xD;
&#xD;
          6. Karnofsky performance status &gt;/=50%&#xD;
&#xD;
          7. Age 18 or older&#xD;
&#xD;
          8. Able to complete study assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Dyspnea at rest &gt;/=7/10 at the time of enrollment&#xD;
&#xD;
          2. Supplemental oxygen requirement &gt;6 L per minute&#xD;
&#xD;
          3. Delirium (i.e. Memorial delirium rating scale &gt;13)&#xD;
&#xD;
          4. History of unstable angina or myocardial infarction 1 month prior to study enrollment&#xD;
&#xD;
          5. Resting heart rate &gt;120 at the time of study enrollment&#xD;
&#xD;
          6. Systolic pressure &gt;180 mmHg or diastolic pressure &gt;100 mmHg at the time of study&#xD;
             enrollment&#xD;
&#xD;
          7. History of active opioid abuse within the past 12 months&#xD;
&#xD;
          8. History of allergy to fentanyl&#xD;
&#xD;
          9. Severe anemia (Hb &lt;7g/L) if documented in the last month and not corrected prior to&#xD;
             study enrollment*&#xD;
&#xD;
         10. Diagnosis of acute pulmonary embolism within past 2 weeks&#xD;
&#xD;
         11. Diagnosis of pulmonary hypertension&#xD;
&#xD;
         12. Unwilling to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <results_first_submitted>October 29, 2020</results_first_submitted>
  <results_first_submitted_qc>December 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 8, 2020</results_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Cancers</keyword>
  <keyword>Fentanyl Sublingual Spray</keyword>
  <keyword>Fentanyl SL Spray</keyword>
  <keyword>FSS</keyword>
  <keyword>Questionnaires</keyword>
  <keyword>Surveys</keyword>
  <keyword>Mental Abilities Test</keyword>
  <keyword>Phone Call</keyword>
  <keyword>Shuttle Walk Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02597478/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult participants (age&gt;18) with an active diagnosis of cancer were recruited between 1/2016 and 10/2018 from the Supportive Care and Thoracic Medical Oncology outpatient clinics at MD Anderson Cancer Center who met the inclusion and exclusion criteria.</recruitment_details>
      <pre_assignment_details>A total of 50 participants enrolled but 34 patients were randomized to start the study. 13 became symptomatic while on wait list and could not proceed, 2 participants died, and 1 had screen failure before participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention Group (High Dose Fentanyl Sublingual Spray)</title>
          <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 35-45% of morphine equivalent daily dose.</description>
        </group>
        <group group_id="P2">
          <title>Controlled Group (Low Dose Fentanyl Sublingual Spray)</title>
          <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 15-20% of morphine equivalent daily dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change of opioid dose</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient exertional dyspnea</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The data is provided for 30 participants who completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Intervention Group (High Dose Fentanyl Sublingual Spray)</title>
          <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 35-45% of morphine equivalent daily dose.</description>
        </group>
        <group group_id="B2">
          <title>Controlled Group (Low Dose Fentanyl Sublingual Spray)</title>
          <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 15-20% of morphine equivalent daily dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="16"/>
                    <measurement group_id="B2" value="51" spread="10"/>
                    <measurement group_id="B3" value="52" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>High school or less</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>College</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advanced degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gynecological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head and Neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Stage</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Metastatic or recurrent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally advanced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Localized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Modified Dyspnea Borg Scale (Dyspnea Intensity)</title>
        <description>The primary outcome was dyspnea intensity &quot;now&quot; using the modified Borg scale, which ranges from 0 (&quot;no shortness of breath&quot;) to 10 (&quot;worst possible shortness of breath&quot;). We measured the change in modified dyspnea Borg scale (0-10) between the first and second shuttle walk tests. This scale has been validated in multiple studies, with a minimal clinically significant difference of 1 point.</description>
        <time_frame>Before and after the first and second shuttle walk tests</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group (High Dose Fentanyl Sublingual Spray)</title>
            <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 35-45% of morphine equivalent daily dose.</description>
          </group>
          <group group_id="O2">
            <title>Controlled Group (Low Dose Fentanyl Sublingual Spray)</title>
            <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 15-20% of morphine equivalent daily dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Dyspnea Borg Scale (Dyspnea Intensity)</title>
          <description>The primary outcome was dyspnea intensity &quot;now&quot; using the modified Borg scale, which ranges from 0 (&quot;no shortness of breath&quot;) to 10 (&quot;worst possible shortness of breath&quot;). We measured the change in modified dyspnea Borg scale (0-10) between the first and second shuttle walk tests. This scale has been validated in multiple studies, with a minimal clinically significant difference of 1 point.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-2.4" upper_limit="-0.5"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-1.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Dyspnea Borg Scale (Dyspnea Unpleasantness)</title>
        <description>The modified Borg scale (dyspnea unpleasantness), which ranges from 0 (&quot;no shortness of breath&quot;) to 10 (&quot;worst possible shortness of breath&quot;). We measured the change in modified dyspnea Borg scale (0-10) between the first and second shuttle walk tests.</description>
        <time_frame>Before and after the first and second shuttle walk tests</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group (High Dose Fentanyl Sublingual Spray)</title>
            <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 35-45% of morphine equivalent daily dose.</description>
          </group>
          <group group_id="O2">
            <title>Controlled Group (Low Dose Fentanyl Sublingual Spray)</title>
            <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 15-20% of morphine equivalent daily dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Dyspnea Borg Scale (Dyspnea Unpleasantness)</title>
          <description>The modified Borg scale (dyspnea unpleasantness), which ranges from 0 (&quot;no shortness of breath&quot;) to 10 (&quot;worst possible shortness of breath&quot;). We measured the change in modified dyspnea Borg scale (0-10) between the first and second shuttle walk tests.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.8"/>
                    <measurement group_id="O2" value="-0.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walk Distance</title>
        <description>We measured the difference in walk distance (in meters) between the first and second shuttle walk tests.</description>
        <time_frame>After the first shuttle walk test and after the second shuttle walk test</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group (High Dose Fentanyl Sublingual Spray)</title>
            <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 35-45% of morphine equivalent daily dose.</description>
          </group>
          <group group_id="O2">
            <title>Controlled Group (Low Dose Fentanyl Sublingual Spray)</title>
            <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 15-20% of morphine equivalent daily dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Walk Distance</title>
          <description>We measured the difference in walk distance (in meters) between the first and second shuttle walk tests.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" lower_limit="25.6" upper_limit="61.8"/>
                    <measurement group_id="O2" value="24.2" lower_limit="5.8" upper_limit="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walk Time</title>
        <description>We measured the difference in walk time (in minutes) between the first and second shuttle walk tests.</description>
        <time_frame>After the first shuttle walk test and after the second shuttle walk test</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group (High Dose Fentanyl Sublingual Spray)</title>
            <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 35-45% of morphine equivalent daily dose.</description>
          </group>
          <group group_id="O2">
            <title>Controlled Group (Low Dose Fentanyl Sublingual Spray)</title>
            <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 15-20% of morphine equivalent daily dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Walk Time</title>
          <description>We measured the difference in walk time (in minutes) between the first and second shuttle walk tests.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.3" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.18" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue Modified Borg Score</title>
        <description>The fatigue modified Borg scale, which ranges from 0 (&quot;none&quot;) to 10 (&quot;worst&quot;). We measured the change in modified fatigue Borg scale (0-10) between the first and second shuttle walk tests.</description>
        <time_frame>Before and after the first and second shuttle walk tests</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group (High Dose Fentanyl Sublingual Spray)</title>
            <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 35-45% of morphine equivalent daily dose.</description>
          </group>
          <group group_id="O2">
            <title>Controlled Group (Low Dose Fentanyl Sublingual Spray)</title>
            <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 15-20% of morphine equivalent daily dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue Modified Borg Score</title>
          <description>The fatigue modified Borg scale, which ranges from 0 (&quot;none&quot;) to 10 (&quot;worst&quot;). We measured the change in modified fatigue Borg scale (0-10) between the first and second shuttle walk tests.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.8"/>
                    <measurement group_id="O2" value="0.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>immediately before drug administration and immediately after the second walk test (approximately 20 min later)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention Group (High Dose Fentanyl Sublingual Spray)</title>
          <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 35-45% of morphine equivalent daily dose.</description>
        </group>
        <group group_id="E2">
          <title>Controlled Group (Low Dose Fentanyl Sublingual Spray)</title>
          <description>Received Fentanyl sublingual spray 10 minutes before performing second shuttle walk test, dose was 15-20% of morphine equivalent daily dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itchiness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Hui, MD/ Associate Professor, Palliative Care Medicine</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 792-6258</phone>
      <email>dhui@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

